UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2017, Volume 317, Issue 1, pp. 37 - 47
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Breast Neoplasms - chemistry | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Biosimilar Pharmaceuticals - therapeutic use | Trastuzumab - therapeutic use | Double-Blind Method | Antineoplastic Agents - immunology | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Remission Induction | Disease Progression | Biosimilar Pharmaceuticals - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Survival Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 | Therapeutic Equipoise | Trastuzumab - immunology | Outcome and process assessment (Health Care) | Care and treatment | Breast cancer | Health aspects | Analysis | Young women | Patient safety | Oncology | Biological products | Biomedical research | Womens health | Index Medicus | Abridged Index Medicus
Journal Article
BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, ISSN 1173-8804, 04/2017, Volume 31, Issue 2, pp. 83 - 91
Pharmacology & Pharmacy | Oncology | Immunology | Life Sciences & Biomedicine | Science & Technology | Etanercept - adverse effects | Filgrastim - adverse effects | Epoetin Alfa - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Human Growth Hormone - adverse effects | Adalimumab - adverse effects | Biosimilar Pharmaceuticals - adverse effects | Adalimumab - therapeutic use | Drug Industry - methods | European Union | Immune System - drug effects | Biosimilar Pharmaceuticals - pharmacokinetics | Etanercept - therapeutic use | Competition | Biotechnology | Biological products | Legislation | Switches | Arthritis | Patients | Insulin | Switching | Proteins | Medicine | Immunogenicity | Gastroenterology | Manufacturing | Product safety | Drug stores
Journal Article
Blood, ISSN 0006-4971, 12/2012, Volume 120, Issue 26, pp. 5111 - 5117
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Education, Medical, Continuing | Professional Practice - trends | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Physicians | Humans | Drug-Related Side Effects and Adverse Reactions - etiology | Biosimilar Pharmaceuticals - pharmacology | Health Knowledge, Attitudes, Practice | Biosimilar Pharmaceuticals - adverse effects | Drug-Related Side Effects and Adverse Reactions - epidemiology | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 10, pp. 968 - 974
Life Sciences & Biomedicine | Oncology | Science & Technology | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Breast Neoplasms - enzymology | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Receptor, ErbB-2 - biosynthesis | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Epirubicin - adverse effects
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 51 - 57
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Biosimilar Pharmaceuticals - therapeutic use | Etanercept - adverse effects | Double-Blind Method | Humans | Middle Aged | Antirheumatic Agents - immunology | Male | Treatment Outcome | Methotrexate - therapeutic use | Biosimilar Pharmaceuticals - adverse effects | Arthritis, Rheumatoid - drug therapy | Etanercept - pharmacokinetics | Etanercept - immunology | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Antibodies - blood | Antirheumatic Agents - pharmacokinetics | Female | Aged | Antirheumatic Agents - therapeutic use | Etanercept - therapeutic use | Therapeutic Equivalency | Treatment outcome | Usage | Care and treatment | Safety and security measures | Etanercept | Rheumatoid arthritis | Analysis | Dosage and administration | Methotrexate | Index Medicus | Anti-TNF | DMARDs (biologic) | Clinical and Epidemiological Research | Rheumatoid Arthritis | 1507 | 1506
Journal Article
Digestive diseases and sciences, ISSN 0163-2116, 2017, Volume 62, Issue 11, pp. 3117 - 3122
Biochemistry, general | Inflammatory bowel diseases | Disease activity | Medicine & Public Health | Infliximab | Switch | Immunogenicity | Hepatology | Gastroenterology | Biosimilar pharmaceuticals | Oncology | Transplant Surgery | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Male | Colitis, Ulcerative - immunology | Infliximab - administration & dosage | Feasibility Studies | Young Adult | Infliximab - adverse effects | Netherlands | Crohn Disease - diagnosis | Tumor Necrosis Factor-alpha - immunology | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Colitis, Ulcerative - drug therapy | Gastrointestinal Agents - pharmacokinetics | Biosimilar Pharmaceuticals - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Crohn Disease - immunology | Biosimilar Pharmaceuticals - adverse effects | Colitis, Ulcerative - diagnosis | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Adolescent | Aged | Gastrointestinal Agents - adverse effects | Drug Substitution | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Therapeutic Equivalency | Index Medicus | Abridged Index Medicus | Original
Journal Article
BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, ISSN 1173-8804, 10/2018, Volume 32, Issue 5, pp. 397 - 404
Antibodies | Pharmacotherapy | Cancer Research | Molecular Medicine | Biomedicine | Pharmacology & Pharmacy | Oncology | Immunology | Life Sciences & Biomedicine | Science & Technology | Biosimilar Pharmaceuticals - therapeutic use | Nocebo Effect | Patient Medication Knowledge | Humans | Physician-Patient Relations | Treatment Outcome | Biosimilar Pharmaceuticals - adverse effects
Journal Article
Clinical and Experimental Rheumatology, ISSN 0392-856X, 2016, Volume 34, Issue 4, pp. 698 - 705
Inflammatory bowel disease | Anti-rheumatic agents | Rheumatoid arthritis | Biosimilar pharmaceuticals | CT-P13 | Therapeutic equivalence | Ankylosing spondylitis | Life Sciences & Biomedicine | Rheumatology | Science & Technology | Rheumatic Diseases - drug therapy | Humans | Inflammatory Bowel Diseases - immunology | Antibodies, Monoclonal - adverse effects | Inflammatory Bowel Diseases - diagnosis | Antibodies, Monoclonal - therapeutic use | Drugs, Generic - therapeutic use | Anti-Inflammatory Agents - adverse effects | Patient Safety | Anti-Inflammatory Agents - therapeutic use | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Anti-Inflammatory Agents - pharmacokinetics | Drug Evaluation, Preclinical | Gastrointestinal Agents - pharmacokinetics | Gastrointestinal Agents - standards | Drugs, Generic - standards | Antirheumatic Agents - therapeutic use | Quality Control | Rheumatic Diseases - immunology | Inflammatory Bowel Diseases - drug therapy | Biosimilar Pharmaceuticals - therapeutic use | Risk Assessment | Antirheumatic Agents - standards | Biosimilar Pharmaceuticals - standards | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Clinical Trials as Topic | Rheumatic Diseases - diagnosis | Patents as Topic | Anti-Inflammatory Agents - standards | Biosimilar Pharmaceuticals - adverse effects | Drugs, Generic - adverse effects | Animals | Drug Approval - methods | Gastrointestinal Agents - therapeutic use | Antirheumatic Agents - pharmacokinetics | Gastrointestinal Agents - adverse effects | Therapeutic Equivalency
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 58 - 64
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Severity of Illness Index | Biosimilar Pharmaceuticals - therapeutic use | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Methotrexate - therapeutic use | Infliximab - immunology | Infliximab - therapeutic use | Infliximab - pharmacokinetics | Biosimilar Pharmaceuticals - adverse effects | Infliximab - adverse effects | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Antibodies - blood | Antirheumatic Agents - pharmacokinetics | Female | Aged | Antirheumatic Agents - therapeutic use | Therapeutic Equivalency | Viral antibodies | Treatment outcome | Care and treatment | Usage | Rheumatoid arthritis | Analysis | Antibodies | Dosage and administration | Methotrexate | Tumor necrosis factor-TNF | Biological products | Tuberculosis | Family medical history | Drug dosages | Index Medicus | Anti-TNF | DMARDs (biologic) | Disease Activity | Clinical and Epidemiological Research | Rheumatoid Arthritis | 1506
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 12, pp. CD010590 - CD010590
Hematinics | Hypertension | Kidney disease | Renal Insufficiency, Chronic | Erythropoietin | Polyethylene Glycols | Anemia | Chronic kidney disease | Recombinant Proteins | Biosimilar Pharmaceuticals | Anaemia control | Epoetin Alfa | General management | Darbepoetin alfa | Medicine General & Introductory Medical Sciences | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Hematinics - therapeutic use | Erythropoietin - therapeutic use | Humans | Erythropoietin - adverse effects | Polyethylene Glycols - adverse effects | Hematinics - adverse effects | Recombinant Proteins - adverse effects | Renal Insufficiency, Chronic - complications | Polyethylene Glycols - therapeutic use | Biosimilar Pharmaceuticals - adverse effects | Erythropoietin - analogs & derivatives | Anemia - drug therapy | Hypertension - chemically induced | Adult | Index Medicus
Journal Article